5 results about "Antineoplastic Immunotherapeutic" patented technology

This invention discloses an immune cell with enhanced anti-tumor effect, its preparation method, and its application. Experiments using this invention show that... SERTAD1 CD8 gene overexpression + T cells can enhance their function in anti-tumor immunotherapy. SERTAD1 Gene overexpression can downregulate CD8 + The expression of immune checkpoint molecules on T cells upregulates the expression of mRNAs of tumor-killing cytokines. In the MC38-OVA subcutaneous tumor model, Naïve CD8 cells were extracted from OT-I mice. + T cells were infected with a virus to overexpress SERTAD1, followed by adoptive transfer to mice. The results showed that SERTAD1 overexpression enhanced CD8 expression. + T cells kill MC38-OVA cells, inhibit the growth of MC38-OVA tumor cells, and overexpress SERTAD1 CD8. + The tumor volume and weight in the T-cell adoptive group were significantly smaller than those in the control group.

The present invention relates to the field of immunotherapy of cancer. In particular, the present invention relates to the role of specific strains of gut bacteria, Akkermansia muciniphila Akkermansia muciniphila ) ibiome016 and ibiome017 in anti-tumor immunity, and provides methods for enhancing the response rate of patients to tumor immunotherapy.

Provided herein are nucleic acids, vectors, viral particles, and nanoparticles for delivering immunogenic cell death executioners, e.g., a N-terminal domain of gasdermin D (GSDMD) and / or a N-terminal domain of Mixed Lineage Kinase Domain Like Pseudokinase (MLKL) to cancer cells. The immunogenic cell death executioners induce necroptosis and pyroptosis, respectively, and are under the control of cancer- (e.g., epithelial cell and / or mesenchymal cell) specific promoters for treating carcinomas (e.g., breast carcinomas).

This invention provides an injectable pH-responsive hydrogel nanoparticle, its preparation method, and its applications, relating to the field of bionanomedicine technology. First, nintedanib, zinc ions, and D780 are self-assembled to prepare nanoparticles (NPs). Then, the nanoparticles are cross-linked with an OP hydrogel to obtain injectable pH-responsive hydrogel nanoparticles (OP@NPs). These OP@NPs not only possess a stable structure and injectability but also achieve efficient drug delivery through a pH-triggered release mechanism. Furthermore, OP@NPs can significantly enhance anti-tumor immune responses and effectively inhibit tumor growth by activating in vivo immune cells, improving lactate metabolism, and enhancing immune cell function. They exhibit potent anti-tumor effects and inhibition of osteosarcoma lung metastasis both in vivo and in vitro. When used in combination with the PD-1 antagonist pembrolizumab, they demonstrate great potential as a sensitizer for anti-tumor immunotherapy. This invention provides innovative strategies and new insights for osteosarcoma immunotherapy.

Provided are an anti-CCR8 antibody and an anti-CCR8 / CTLA-4 bispecific antibody, and the use thereof. Further provided are a polynucleotide, recombinant vector, host cell, chimeric antigen receptor, antibody conjugate, pharmaceutical composition and kit related to the anti-CCR8 antibody and anti-CCR8 / CTLA-4 bispecific antibody, and the related use and method. The provided antibodies can specifically target and eliminate regulatory T lymphocytes with an immunosuppressive activity infiltrating tumor tissue, and can be used in anti-tumor immunotherapy.